Compare KB & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KB | ONC |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | South Korea | Switzerland |
| Employees | N/A | 12000 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.2B | 40.6B |
| IPO Year | 2008 | 2015 |
| Metric | KB | ONC |
|---|---|---|
| Price | $126.55 | $349.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $385.10 |
| AVG Volume (30 Days) | 143.0K | ★ 282.9K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ 140.43 |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | ★ $238,387,000.00 |
| Revenue This Year | $18.22 | $723.76 |
| Revenue Next Year | $3.21 | $15.04 |
| P/E Ratio | ★ $9.90 | $1,127.06 |
| Revenue Growth | N/A | ★ 22179.16 |
| 52 Week Low | $77.44 | $253.95 |
| 52 Week High | $133.08 | $385.22 |
| Indicator | KB | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 46.62 |
| Support Level | $112.97 | $327.01 |
| Resistance Level | N/A | $353.10 |
| Average True Range (ATR) | 1.96 | 7.10 |
| MACD | 0.68 | -4.36 |
| Stochastic Oscillator | 68.60 | 14.62 |
KB Financial Group Inc. is a financial holding company in Korea. The company operations include Kookmin Bank, one of the commercial banks in Korea. The company's subsidiaries collectively engage in a broad range of businesses, including commercial banking, credit cards, asset management, non-life and life insurance, capital markets activities, and international banking and finance. The company's segments include the Banking business, Securities business, Non-life Insurance business, Credit card business, and Life Insurance business. The Group generates the majority of its revenue from the Banking business.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.